FDA Peptide Hearing: What July 2026 Means
The Pharmacy Compounding Advisory Committee meets July 23-24, 2026 to review 7 peptides for the 503A Bulk Drug Substances List. If approved, licensed pharmacies regain the legal authority to compound BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, and Epitalon. The biggest peptide-policy event of the year.
PCAC Review
Comment Deadline
Queued for Feb 2027
How It Works
BPC-157 (wound healing, ulcerative colitis), KPV (UC), TB-500 (wound healing), MOTS-c (obesity). PCAC votes on whether these belong on the 503A bulks list — the legal precondition for compounding pharmacy access.
Emideltide / DSIP (insomnia), Semax (opioid withdrawal), Epitalon (anti-aging). All three were Category 2 (banned from compounding) since the 2023 reclassification — this is their reinstatement hearing.
Current review covers ONLY the 503A list (licensed pharmacies serving individual patients). The 503B outsourcing-facility status remains unresolved. Even if 503A approves, large-scale commercial compounding (telehealth supply at scale) requires separate 503B action.
Public comment window closes July 22, 2026 — one day before the meeting. Patient testimony, prescriber data, and safety/efficacy evidence carry weight in the PCAC vote. Industry mobilization is heavy.
What the Data Shows
Key Takeaways
- PCAC meets July 23-24, 2026 at FDA White Oak Campus
- Day 1: BPC-157, KPV, TB-500, MOTS-c reviewed for 503A bulks list
- Day 2: DSIP (Emideltide), Semax, Epitalon reviewed
- Public docket FDA-2025-N-6895 closes for comments July 22, 2026
- February 2027 follow-up will review GHK-Cu, Melanotan II, LL-37, Dihexa, PEG-MGF
- CJC-1295, Ipamorelin, and Thymosin Alpha-1 are NOT on this agenda but reinstatement is expected per HHS reclassification efforts
- 503B outsourcing-facility status (commercial-scale supply) remains separate and unresolved
- How PCAC will vote on each peptide (recommendations carry weight but FDA makes final ruling)
- Whether 503B status follows quickly if 503A is approved
- Timeline between PCAC vote and FDA final rule (typically 6-18 months)
- How compounding pricing reshapes once licensed pharmacies legally re-enter the market
- Whether enforcement against gray-market research-peptide vendors intensifies post-ruling
Frequently Asked Questions
What is the FDA July 2026 peptide hearing?
The Pharmacy Compounding Advisory Committee (PCAC) meets July 23-24, 2026 at the FDA White Oak Campus to review whether seven peptides — BPC-157, KPV, TB-500, MOTS-c, DSIP/Emideltide, Semax, and Epitalon — should be added to the Section 503A Bulk Drug Substances List. Inclusion on the 503A list is the legal precondition for licensed pharmacies to compound these peptides for individual patient prescriptions. Public docket FDA-2025-N-6895 accepts comments until July 22, 2026.
Will BPC-157 be legal to compound after this hearing?
Possibly. PCAC votes are advisory; FDA issues the final rule typically 6-18 months later. If the committee recommends inclusion AND the FDA agrees, licensed 503A pharmacies will be able to compound BPC-157 with a valid patient-specific prescription. Note that 503B outsourcing-facility status (commercial-scale supply for telehealth providers) is a separate process not addressed at this hearing.
Why are CJC-1295 and Ipamorelin not on the agenda?
They were moved to Category 2 in 2023 and became part of an industry lawsuit against the FDA over the reclassification. They are not listed for the July 2026 PCAC review, but per HHS Secretary Kennedy's peptide-reclassification effort, reinstatement is widely expected on a later docket. No specific date is confirmed as of April 2026.
What about Thymosin Alpha-1?
Same status — restricted in 2023, part of the litigation, not on the July 2026 agenda but expected to return to compounding access on a future docket. Practitioners and patients should monitor PCAC announcements through 2027.
How can I influence the outcome?
Submit a public comment to docket FDA-2025-N-6895 before July 22, 2026. Patient testimony of clinical use and safety, prescriber documentation of off-label experience, and peer-reviewed evidence all factor into the PCAC discussion. Visit regulations.gov, search the docket number, and submit through the official portal.
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
Educational purposes only. Not medical advice.
Regulatory status of compounded peptides evolves rapidly. Verify current FDA guidance and applicable state pharmacy law before relying on this page for legal interpretation.